Prolonging the life of those with Cystic Fibrosis

via Queen’s University Belfast

Scientists at Queen’s University Belfast have discovered a new molecule which has the potential to prolong the life of individuals with cystic fibrosis (CF).

The molecule represents a possible future treatment and works by altering cellular ion channels resulting in improved airway hydration and significantly increased mucus clearance.

For individuals with CF, normal airway clearance mechanisms which keep the lungs free of infection are defective. As a result, a build-up of mucus occurs and predisposes the individual to chronic bacterial infection. The ensuing cycles of chronic infection and airway inflammation cause progressive destruction of the airways, which is ultimately fatal.

The innovative approach could reduce the frequency of these infections through a novel protease inhibitor which prevents activation of the epithelial sodium channel; ENaC.

The research involved a team of scientists from Queen’s University alongside colleagues at the Royal College of Surgeons in Ireland and the University of North Carolina, and was funded by The Cystic Fibrosis Trust.

Speaking about the breakthrough, Dr Lorraine Martin from the School of Pharmacy at Queen’s University Belfast, said: “This is an important finding which could provide a novel therapeutic opportunity relevant to all individuals with CF, as the targeting of ENaC is independent of their underlying CF mutation. This strategy could prevent the significant lung damage that results from chronic cycles of infection and inflammation, with potential impact on quality of life as well as life expectancy. This is a further example of Queen’s University’s research advancing knowledge and changing lives.”

Ed Owen, Chief Executive at the Cystic Fibrosis Trust, said: “We are thrilled with these initial findings and are excited to see how the next stage of preclinical testing progresses. We are pleased to have been able to fund this world class project at its early stage and welcome the drug development programme planned over the coming years. Research is the biggest single area of investment for the Cystic Fibrosis Trust and it’s wonderful to see projects like this making such positive progress in our fight for a life unlimited.”

Currently available pharmacological alternatives are only suitable for a small subset of patients depending on the disease-causing genetic mutation.

Learn more: QUEEN’S SCIENTISTS DEVELOP NEW TREATMENT TO PROLONG LIFE OF THOSE WITH CYSTIC FIBROSIS

The Latest on: Cystic Fibrosis

[google_news title=”” keyword=”Cystic Fibrosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]

via Google News

The Latest on: Cystic Fibrosis

Could Vertex’s cystic fibrosis medicines hold a clue to treating deadly pneumonia?
on December 7, 2022 at 11:01 am
Although still early, a new study suggests that a new line of drugs for cystic fibrosis could moonlight as a treatment for ARDS, the lung condition that killed millions in the pandemic.
Sionna Therapeutics Announces IND Clearance and Phase 1 Initiation for SION-638 in Cystic Fibrosis
on December 7, 2022 at 5:18 am
First-in-class small molecule designed to target the NBD1 domainof the CFTR protein -- First subject dosed in Phase 1 study -BOSTON, Dec. 7, ...
Former Palm Beach County firefighter accused of stealing from cystic fibrosis charity
on December 7, 2022 at 2:01 am
Piper's Angels is a nonprofit incorporated in 2016 for the purpose of providing support to people diagnosed with cystic fibrosis — a genetic disorder that causes problems with breathing and digestion ...
Cystic Fibrosis Foundation Announces Irena Barisic as Next Chief Operating and Financial Officer
on December 6, 2022 at 6:00 am
Barisic Will Transition from Current Role as Chief Financial and Administrative Officer in January 2023 ...
Rotorua cystic fibrosis sufferers celebrate funding of ‘miracle drug’ Trikafta
on December 5, 2022 at 9:00 am
Cystic fibrosis sufferers around the Bay of Plenty are celebrating after Pharmac announced on Sunday funding of the “miracle drug” Trikafta is proposed to start on April 1.
Bay of Plenty cystic fibrosis sufferers celebrate funding of ‘miracle drug’ Trikafta
on December 5, 2022 at 9:00 am
Cystic fibrosis sufferers in the Bay of Plenty are celebrating after Pharmac announced funding of the “miracle drug” Trikafta is proposed to start on April 1.
Covington 4-year-old with Cystic Fibrosis receives new lungs
on December 5, 2022 at 6:52 am
A 4-year-old who had cystic fibrosis was able to replace her lungs via surgery thanks to the donation of another family.
4-year-old Covington girl with cystic fibrosis receives new lungs
on December 5, 2022 at 2:49 am
The 4-year-old Covington girl with cystic fibrosis we told you about last week received new lungs on Monday. Ava Thomas was diagnosed with cystic fibrosis (CF) at three weeks old. CF is a rare genetic ...
4-year-old girl with cystic fibrosis receives new lungs
on December 5, 2022 at 2:46 am
A 4-year-old who had cystic fibrosis was able to replace her lungs via surgery thanks to the donation of another family.
Cystic Fibrosis NZ: Provisional agreement for Trikafta funding is a miracle
on December 4, 2022 at 11:31 pm
Funding for a Cystic Fibrosis drug is being described as a miracle. A provisional agreement's been made between Pharmac and Vertex to fund the drug Trikaft ...